Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Rhea-AI Summary
Compugen (Nasdaq:CGEN), a clinical-stage cancer immunotherapy company using AI/ML for computational target discovery, will present at the 2026 Stifel Virtual Targeted Oncology Forum.
The management presentation is scheduled for May 19, 2026, 10:00–10:25 AM ET, with live webcast and replay via Compugen’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – CGEN
In the May 12 session, CGEN declined 1.39%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Earnings date notice | Neutral | -2.6% | Announcement of upcoming Q1 2026 results and conference call schedule. |
| Apr 09 | Conference participation | Neutral | +8.3% | Plan to present at Needham virtual healthcare conference with webcast access. |
| Mar 02 | Earnings and update | Positive | +24.3% | Reported FY 2025 results, cash position, royalty monetization and clinical progress. |
| Feb 19 | Multiple conferences | Neutral | +5.3% | Participation in two late‑Feb and early‑Mar 2026 investor healthcare conferences. |
| Feb 17 | Earnings date notice | Neutral | +1.8% | Scheduled release date and call for Q4 and FY 2025 financial results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and major corporate updates have seen strong positive reactions, while routine conference and event notices typically produced modest single‑digit moves in either direction.
Over the last few months, Compugen’s key milestones included a strong Q4/FY 2025 report on Mar 2 (news_id 1020608) with a 24.31% next‑day gain, and several conference and earnings‑date announcements. Event notices on Feb 19 and Apr 9 (news_id 1015285, 1037594) led to gains of 5.29% and 8.3%, while earnings‑date reminders on Feb 17 and May 4 saw smaller moves. Today’s forum participation fits this ongoing pattern of regular investor‑relations visibility.
Key Terms
immunotherapy medical
ai/ml technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, Compugen is conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Investor relations
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-2026-stifel-virtual-targeted-oncology-forum-302769368.html
SOURCE Compugen Ltd.